{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:28:00Z","timestamp":1757618880688,"version":"3.44.0"},"reference-count":30,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2024,7,23]]},"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1136\/ejhpharm-2024-004227","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T14:28:43Z","timestamp":1722436123000},"page":"376-380","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term stability of esketamine in polypropylene syringes at 5 \u00b1 3\u00b0C"],"prefix":"10.1136","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-1084","authenticated-orcid":false,"given":"Am\u00e9lie","family":"Kinet-Poleur","sequence":"first","affiliation":[{"name":"Department of Medical Laboratory, CHU UCL Namur, Yvoir, Belgium"},{"name":"Drug Stability Research Group, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Lise","family":"Colsoul","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory, CHU UCL Namur, Yvoir, Belgium"},{"name":"Drug Stability Research Group, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Catry","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory, CHU UCL Namur, Yvoir, Belgium"},{"name":"Drug Stability Research Group, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet P","family":"Bihin","sequence":"additional","affiliation":[{"name":"Drug Stability Research Group, CHU UCL Namur, Yvoir, Belgium"},{"name":"Scientific Support Unit, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara E","family":"Sneyers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, CHU UCL Namur, Yvoir, Belgium"},{"name":"Drug Stability Research Group, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Hubert","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, CHU UCL Namur, Yvoir, Belgium"},{"name":"Drug Stability Research Group, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Jamart","sequence":"additional","affiliation":[{"name":"Drug Stability Research Group, CHU UCL Namur, Yvoir, Belgium"},{"name":"Scientific Support Unit, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Soumoy","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, CHU UCL Namur, Yvoir, Belgium"},{"name":"Drug Stability Research Group, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence M","family":"Galanti","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory, CHU UCL Namur, Yvoir, Belgium"},{"name":"Drug Stability Research Group, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Daniel","family":"Hecq","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, CHU UCL Namur, Yvoir, Belgium"},{"name":"Drug Stability Research Group, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Closset","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory, CHU UCL Namur, Yvoir, Belgium"},{"name":"Drug Stability Research Group, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"2025090701382504000_32.4.376.1","unstructured":"Vesierra . Summary of product characteristics. Federal agency for medicines and health products; 2022. Available: https:\/\/www.cbip.be\/fr\/chapters\/19?frag=8900193&trade_family=41616"},{"key":"2025090701382504000_32.4.376.2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pharma.2010.09.002","article-title":"Centralized intravenous additive services (CIVAS): the state of the art in 2010","volume":"69","author":"Hecq","year":"2011","journal-title":"Ann Pharm Fr"},{"key":"2025090701382504000_32.4.376.3","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2016-001154"},{"key":"2025090701382504000_32.4.376.4","first-page":"299","article-title":"La ketamine en m\u00e9decine d\u2019urgence: une mol\u00e9cule ancienne\u2026 qui a de l\u2019avenir!","volume":"140","author":"Bellemans","year":"2021","journal-title":"Louvain Med"},{"key":"2025090701382504000_32.4.376.5","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.bja.2018.08.023","article-title":"Effect of intravenous S-ketamine on the MAC of sevoflurane: a randomised, placebo-controlled, double-blinded clinical trial","volume":"121","author":"Hamp","year":"2018","journal-title":"Br J Anaesth"},{"key":"2025090701382504000_32.4.376.6","doi-asserted-by":"crossref","first-page":"693594","DOI":"10.3389\/fmed.2021.693594","article-title":"Effects of esketamine on acute and chronic pain after thoracoscopy pulmonary surgery under general anesthesia: a multicenter-prospective, randomized, double-blind, and controlled trial","volume":"8","author":"Lei","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025090701382504000_32.4.376.7","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2147\/DDDT.S356284","article-title":"Global trends and hotspots in esketamine research: a bibliometric analysis of past and estimation of future trends","volume":"16","author":"Li","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"2025090701382504000_32.4.376.8","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003299"},{"key":"2025090701382504000_32.4.376.9","doi-asserted-by":"publisher","DOI":"10.1097\/AAP.0000000000000806"},{"key":"2025090701382504000_32.4.376.10","unstructured":"Haute autorit\u00e9 de sant\u00e9 retranscription. Commission de la Transparence . Evaluation de l\u2019Esk\u00e9tamine. 2021. Available: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-08\/esketamine_02062021_transcription_ct18966.pdf"},{"key":"2025090701382504000_32.4.376.11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fmed.2020.00407","article-title":"Practical implications from European hospital pharmacists on prospective risk assessment for medicine shortages","volume":"7","author":"Miljkovi\u0107","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2025090701382504000_32.4.376.12","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/ajhp\/zxaa219","article-title":"Dynamic pharmacy leadership during the COVID-19 crisis: optimizing patient care through formulary and drug shortage management","volume":"77","author":"Pulk","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2025090701382504000_32.4.376.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2015.12.005"},{"key":"2025090701382504000_32.4.376.14","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000005457"},{"key":"2025090701382504000_32.4.376.15","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5340","article-title":"Stability evaluation of morphine, hydromorphone, metamizole and esketamine containing analgesic mixtures applied for patient-controlled analgesia in hospice and palliative care","volume":"36","author":"Harder","year":"2022","journal-title":"Biomed Chromatogr"},{"key":"2025090701382504000_32.4.376.16","unstructured":"Hecq JD . Stabilit\u00e9 des m\u00e9dicaments injectables en perfusion edition 2022 40 ans de recherche bibliographique. Association Francophone des Pharmaciens Hospitaliers de Belgique, 2022."},{"key":"2025090701382504000_32.4.376.17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1515\/pthp-2019-0012","article-title":"European databases on stability and compatibility of injectable medicinal products in Europe","volume":"4","author":"Hecq","year":"2019","journal-title":"Pharm Technol Hosp Pharm"},{"key":"2025090701382504000_32.4.376.18","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2016-001045"},{"key":"2025090701382504000_32.4.376.19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.pharma.2016.03.003","article-title":"Long-term stability of ketamine hydrochloride 50mg\/ml injection in 3ml syringes","volume":"74","author":"Huvelle","year":"2016","journal-title":"Ann Pharm Fr"},{"key":"2025090701382504000_32.4.376.20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4212\/cjhp.v62i1.114","article-title":"Physical compatibility and chemical stability of ketamine-morphine mixtures in polypropylene syringes","volume":"62","author":"Donnelly","year":"2009","journal-title":"Can J Hosp Pharm"},{"key":"2025090701382504000_32.4.376.21","doi-asserted-by":"crossref","unstructured":"Colsoul ML , Hecq JD , Soumoy L . Long-term stability of an infusion containing morphine, ketamine and lorazepam in syringe at 5\u00b13\u00b0C. J Pharma Pharma Sci 2019;4. doi:10.29011\/2574-7711.100082","DOI":"10.29011\/2574-7711.100082"},{"key":"2025090701382504000_32.4.376.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2009.05.008"},{"key":"2025090701382504000_32.4.376.23","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH 2005 . Validation of analytical procedures: text and methodology Q2(R1). Geneva International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2005. Available: https:\/\/database.ich.org\/sites\/default\/files\/Q2%28R1%29%20Guideline.pdf"},{"key":"2025090701382504000_32.4.376.24","unstructured":"Rawat T , Pandey IP . Forced degradation studies for drug substances and drug products- scientific and regulatory considerations. J Pharm Sci 2015;7."},{"key":"2025090701382504000_32.4.376.25","unstructured":"International Conference on Harmonization (ICH) . Guidance for industry Q1E: evaluation of stability data. Geneva International Conference on Harmonization (ICH); 2004. Available: https:\/\/database.ich.org\/sites\/default\/files\/Q1E_Guideline.pdf"},{"key":"2025090701382504000_32.4.376.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2011.07.002"},{"key":"2025090701382504000_32.4.376.27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.pharma.2013.06.002","article-title":"SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update","volume":"71","author":"Vigneron","year":"2013","journal-title":"Ann Pharm Fr"},{"key":"2025090701382504000_32.4.376.28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1208\/s12249-012-9815-2","article-title":"On the shelf life of pharmaceutical products","volume":"13","author":"Capen","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"2025090701382504000_32.4.376.29","doi-asserted-by":"crossref","unstructured":"Crauste-Manciet S , Kr\u00e4mer I , Lagarce F , et al . GERPAC consensus conference \u2013 guidance on the assignment of microbiological shelf-life for hospital pharmacy aseptic preparations. Pharm Technol Hosp Pharm 2020;5. doi:10.1515\/pthp-2020-0001","DOI":"10.1515\/pthp-2020-0001"},{"key":"2025090701382504000_32.4.376.30","unstructured":"The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products (CPMP) . Note for guidance on maximum shelf-life for sterile products for human use after first opening or following reconstitution. London. 1998. Available: https:\/\/www.ema.europa.eu\/en\/maximum-shelf-life-sterile-products-human-use-after-first-opening-or-following-reconstitution-scientific-guideline"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2024-004227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:38:37Z","timestamp":1757234317000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2024-004227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/ejhpharm-2024-004227"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2024-004227","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"type":"print","value":"2047-9956"},{"type":"electronic","value":"2047-9964"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}